Brief: Syndax Pharmaceuticals Q2 EPS USD -0.83

Syndax Pharmaceuticals

04/08/2025 21:01

Overview

 Q2 net loss of $71.8 mln, or $0.83 per share, versus loss of $68.1 million, or $0.80 per share year ago

Syndax Q2 Revuforj rev grows 43% compared with first quarter

Niktimvo shows significant growth in first full quarter of U.S. launch

Co holds $517.9 mln in cash, supporting path to profitability

Outlook

Syndax expects stable expenses over the next few years

Company anticipates reaching profitability with current cash reserves

Syndax expects full-year 2025 operating expenses of $370 to $390 mln

Company not providing revenue guidance at this time

Result Drivers

REVUFORJ GROWTH - Revuforj net revenue rose 43% quarter-over-quarter, driven by deeper penetration into the KMT2A population and patient recontinuations post-transplant

NIKTIMVO LAUNCH - Niktimvo achieved significant revenue growth in its first full quarter of U.S. launch, contributing to profitability

STABLE EXPENSES - Syndax expects stable expenses over the next few years, aiding its path to profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.83
Q2 Net Income
-$71.85 mln
Q2 Cash & Investments
$517.90 mln
Q2 Operating Expenses
$107.31 mln
Q2 Operating Income
-$69.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $33.50, about 70.2% above its August 1 closing price of $9.98

Press Release: ID:nGNXcdPLNk

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)